insulin receptor antibody

Ersodetug for Refractory Hypoglycemia Due to Malignant Insulin-Secreting Tumors: A Compassionate Use Case Series

This case series describes compassionate use of ersodetug in eight adults with refractory hypoglycemia from malignant insulin-secreting tumors, demonstrating improved glycemic control, reduced hypoglycemia, and enhanced functional status.